The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Biomarker analysis of WJOG4107, a randomized phase II trial of adjuvant chemotherapy with S-1 versus CDDP+S-1 for resected stage II-IIIA non-small cell lung cancer (NSCLC).
Tetsuya Mitsudomi
No relevant relationships to disclose
Yasuo Iwamoto
No relevant relationships to disclose
Kazuto Nishio
No relevant relationships to disclose
Takeharu Yamanaka
No relevant relationships to disclose
Hiroshige Yoshioka
Honoraria - Taiho Pharmaceutical
Hirohito Tada
No relevant relationships to disclose
Masahiro Yoshimura
No relevant relationships to disclose
Ichiro Yoshino
Research Funding - Taiho Pharmaceutical
Isamu Okamoto
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Shinzoh Kudoh
No relevant relationships to disclose
Nobuyuki Yamamoto
No relevant relationships to disclose
Mitsunori Ohta
No relevant relationships to disclose
Yukito Ichinose
Honoraria - Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Shinji Atagi
No relevant relationships to disclose
Morihito Okada
Research Funding - Taiho Pharmaceutical (B)
Hideo Saka
No relevant relationships to disclose
Nobuyuki Katakami
No relevant relationships to disclose
Kazuhiko Nakagawa
Honoraria - Taiho Pharmaceutical
Yoichi Nakanishi
No relevant relationships to disclose